(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist

Lorella Pasquinucci, Rita Turnaturi, Girolamo Calò, Francesco Pappalardo, Federica Ferrari, Giulia Russo, Emanuela Arena, Lucia Montenegro, Santina Chiechio, Orazio Prezzavento, Carmela Parenti

PII: S0223-5234(19)30157-6
DOI: https://doi.org/10.1016/j.ejmech.2019.02.043
Reference: EJMECH 11135

To appear in: European Journal of Medicinal Chemistry

Received Date: 23 November 2018
Revised Date: 11 February 2019
Accepted Date: 11 February 2019


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): discovery of a biased mu/delta opioid receptor agonist

Lorella Pasquinucci\textsuperscript{a}, Rita Turnaturi\textsuperscript{a*}, Girolamo Cal\textsuperscript{b}, Francesco Pappalardo\textsuperscript{c}, Federica Ferrari\textsuperscript{b}, Giulia Russo\textsuperscript{d}, Emanuela Arena\textsuperscript{a}, Lucia Montenegro\textsuperscript{e}, Santina Chiechio\textsuperscript{c,d}, Orazio Prezzavento\textsuperscript{a,1} and Carmela Parenti\textsuperscript{c,1}

\textsuperscript{a} Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, Viale A. Doria 6, 95125 Catania, Italy

\textsuperscript{b} Department of Medical Sciences, Pharmacology section, University of Ferrara, via Fossato di Mortara 19, 44121 Ferrara, Italy

\textsuperscript{c} Department of Drug Sciences, Pharmacology and Toxicology Section, University of Catania, Viale A. Doria 6, 95125 Catania, Italy

\textsuperscript{d} Department of Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia 97, 95125 Catania, Italy

\textsuperscript{e} Department of Drug Sciences, Pharmaceutical Technology Section, University of Catania, Viale A. Doria 6, 95125 Catania, Italy

\textsuperscript{f} Oasi Research Institute-IRCCS, Troina, Italy

* Corresponding author.

E-mail address: rita.turnaturi@unict.it (Rita Turnaturi)

\textsuperscript{1} O.P. and C.P. contributed equally to the work.

Graphical Abstract
Highlights

1. The stereocenter role at the N-substituent of the 6,7-benzomorphan scaffold was investigated.
2. 2R- and 2S-diastereoisomers of the multitarget opioid ligand LP2 were synthesized.
3. 2S-LP2 showed a better pharmacological profile than 2R-LP2 in in vitro and in vivo assays.
4. 2S-LP2 resulted a biased multitarget MOR/DOR agonist.
5. 2S-LP2 elicited an antinociceptive potency 1.5- and 3-times higher than LP2 and R-antipode.

Keywords Pain; Multitarget; Asymmetric synthesis; Radioligand competition binding; BRET; G-protein; β-arrestin; Tail Flick test.
Abstract

The pivotal role of the stereocenter at the \(N\)-substituent of the 6,7-benzomorphan scaffold was investigated combining synthetic and pharmacological approaches. 2\(R\)- and 2\(S\)-diastereoisomers of the multitarget MOR/DOR antinociceptive ligand LP2 (1) were synthesized and their pharmacological profile was evaluated in in vitro and vivo assays. From our results, 2\(S\)-LP2 (5) showed an improved pharmacological profile in comparison to LP2 (1) and 2\(R\)-LP2 (4). 2\(S\)-LP2 (5) elicited an antinociceptive effect with a 1.5- and 3-times higher potency than LP2 (1) and \(R\)-antipode (4), respectively. In vivo effect of 2\(S\)-LP2 (5) was consistent with the improved MOR/DOR efficacy profile assessed by radioligand binding assay, to evaluate the opioid receptor affinity, and BRET assay, to evaluate the capability to promote receptor/G-protein and receptor/\(\beta\)-arrestin 2 interactions. 2\(S\)-LP2 (5) was able to activate, with different efficacy, G-protein pathway over \(\beta\)-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. Considering the therapeutic potential of both multitarget MOR/DOR agonism and functional selectivity over G-protein, the 2\(S\)-LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity.

1. Introduction

Currently used analgesic drugs are chiral compounds often marketed as racemic mixture [1] or single eutomers rather than distomers [2]. For instance, both isomers contribute to the analgesic effect of Tramadol, marketed as mixture 1:1 of \(1R,2R\)-(+)- and \(1S,2S\)-(-)-isomers, with a different but complementary mechanism of action [3], while in Nucynta® the pharmacological

\(^{1}\) SAR, structure-activity relationship; MOR, mu opioid receptor; DOR, delta pioid receptor; GPI, guinea pig ileum; MVD, mouse vas deferens; BRET, bioluminescence resonance energy transfer; KOR, kappa opioid receptor; i.p., intraperitoneal; TFL, tail flick latency.
effect is due to the $1R,2R$-Tapentadol isomer [4]. Thus, drug chirality is assumed to have an important role in both design and development of new analgesic drugs. Despite the fact that isomers share the identical molecular formulas, atom-to-atom linkages, and bonding distances, they are different chemical compounds. Indeed, the isomers could differ in pharmacological, pharmacokinetic and toxicological properties [5] because of the environment of living systems where drug targets are also chiral. Thus, the stereoselective isomer-target interaction could result in different affinity, selectivity and activity, generating substantial differences between isomers [6].

Recently, we synthesized a series of 6,7-benzo[c]morphinan-based compounds bearing short and flexible substituents at the basic nitrogen [7]. This SAR study confirmed the importance of N-substituent nature in opioid receptors affinity and/or activity modulation. In particular, the increased flexibility of the N-substituent and the presence of a hydroxyl or methoxyl group at carbon 2, as hydrogen bond donor and acceptor, allowed an optimal interaction with the opioid receptor binding pocket. Among them, the compound with the ($R$/$S$)-2-methoxy-2-phenylethyl group as N-substituent, named LP2 (I, Fig. 1), was characterized by nanomolar affinity for MOR ($K_i = 1.08$ nM) DOR ($K_i = 6.61$ nM) and KOR ($K_i = 15.22$ nM) (Table 1) and in vitro assays (GPI and MVD) LP2 showed MOR/DOR agonist profile ($IC_{50}^{MOR} = 21.5$ nM and $IC_{50}^{DOR} = 4.4$ nM). In the tail flick test, after i.p. administration, LP2 produced a long-lasting antinociception, naloxone-reversed, with an $ED_{50}$ of 0.9 mg/kg. Collected data highlighted that LP2 is a multitarget MOR/DOR antinociceptive ligand. Compounds possessing multitarget opioid activity are effective antinociceptive agents with limited adverse effects. In fact, a growing body of evidence [8,9] suggested that in such opioid ligands the additive or synergic antinociceptive
effects coupled with an improved tolerability could be the result of MOR/DOR intermodulatory interactions [10,11].

In the present study, to investigate the role of the stereocenter at the N-substituent of the 6,7-benzomorphan scaffold [12,13] in drug-opioid receptor interaction, we evaluated the pharmacological fingerprint of both 2R- (4) and 2S- (5) diastereoisomers (Fig. 1) of the multitarget MOR/DOR agonist LP2 (1) using a combination of synthetic and pharmacological approaches. To this aim, LP2 diastereoisomers were synthesized. Both diastereoisomers were tested in vitro by competition binding and BRET assays, and in vivo by tail flick test. The pharmacological profile of 2R-LP2 (4) and 2S-LP2 (5) were compared each other and with LP2 (1).

![Fig. 1. LP2, 2R-LP2, 2S-LP, 2R-OH and 2S-OH structures.](image)

2. Results and discussion

2.1. Chemistry

To obtain compounds 2R-LP2 (4) and 2S-LP2 (5), an asymmetric approach was performed as previously reported (Scheme 1) [7]. By means of resolution of commercially available racemic mixture, the (−)-cis-N-normetazocine was obtained as previously reported [14,15]. Compounds 2 and 3 were prepared by primary alcohol sulfonylation with pTsCl and TEA in CH₂Cl₂ with
catalytic Bu₂SnO. Target compounds 2R-LP2 (4) and 2S-LP2 (5) were obtained by alkylation of 
(-)-cis-N-normetazocine with the respective tosylated alcohols 2 and 3. All compounds were 
characterized by ¹H and ¹³C NMR, IR mass spectroscopy and elemental analysis.

**Scheme 1.** Synthetic pathway.

![Scheme 1](image)

Reagents and conditions: a) TsCl, TEA, Bu₂SnO, CH₂Cl₂, rt, 3 h; b) (-)-cis-N-normetazocine, 
NaHCO₃, KI, DMF, 65 °C, 24 h.

2.2. Radioligand binding assay

MOR, DOR and KOR binding affinity was determined by radioligand competition binding 
experiments on rat or guinea pig brain membranes as previously reported [16]. Inhibition 
constant (Kᵢ) values, calculated using nonlinear regression analysis (GraphPad Prism, version 
5.0), are listed in Table 1.
Table 1. Opioid receptor binding affinity of LP2 (1), 2R-LP2 (4) and 2S-LP2 (5) on rat or guinea pig brain membranes.

<table>
<thead>
<tr>
<th>Compd</th>
<th>Kᵢ (nM) ± SEM</th>
<th>Kᵢ ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MOR</td>
<td>DOR</td>
</tr>
<tr>
<td>LP2 (1)</td>
<td>1.08 ± 0.10</td>
<td>6.61 ± 0.60</td>
</tr>
<tr>
<td>2R-LP2 (4)</td>
<td>12.30 ± 0.42</td>
<td>151.10 ± 0.60</td>
</tr>
<tr>
<td>2S-LP2 (5)</td>
<td>0.50 ± 0.03</td>
<td>2.59 ± 0.05</td>
</tr>
<tr>
<td>DAMGO</td>
<td>1.16 ± 0.10</td>
<td>-</td>
</tr>
<tr>
<td>Naltrindole</td>
<td>-</td>
<td>1.13 ± 0.10</td>
</tr>
<tr>
<td>U50,488</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* Values are means ± SEM of three separate experiments, each carried out in duplicate.

** Kᵢ values were obtained as [³H]-DAMGO displacement for MOR, [³H]-DPDPE displacement for DOR, and [³H]-(+)-U69,593 displacement for KOR, using nonlinear regression analysis (GraphPad Prism, version 5.0).

All compounds displayed the capability to inhibit [³H]-DAMGO binding at MOR in a concentration-dependent manner. In comparison to LP2 (1), MOR Kᵢ values were 11-times higher for 2R-LP2 (4) and 2-times lower for the 2S-antipode (5). 2R-LP2 (4) DOR affinity was 23-times lower than that of LP2 (1). Differently, 2S-LP2 (5) showed a DOR affinity about 3- and 58-times higher than that of LP2 (1) and 2R-antipode (4), respectively. We also found that KOR affinity of 2R-LP2 and 2S-LP2 (4 and 5) was lower than that of LP2 (1). Specifically, 2S-LP2 (5) KOR affinity resulted 2-times lower, while 2R-LP2 (4) KOR affinity was 15-times reduced in comparison to the LP2 (1) KOR affinity.

The 2-methoxy-2-phenylethyl N-substituent of LP2 (1) provides a high affinity for MOR and DOR and a moderate affinity for KOR [7]. The results of this study showed that 2R configuration (4) seemed to be tolerated by MOR but not by DOR and KOR, whereas an improved binding profile at both MOR and DOR was recorded for compound (5) with the 2S-configuration at the 2-methoxy-2-phenylethyl N-substituent.
Previously [7], we reported an analogous trend highlighting the influence of $N$-substituent stereochemistry. Indeed, the 6,7-benzomorphan compound with the 2S-hydroxy-2-phenylethyl as $N$-substituent (2S-OH, 7, Figure 1) showed the best MOR (K_i = 0.50 ± 0.20 nM), DOR (K_i = 0.80 ± 0.20 nM) and KOR (K_i = 2.22 ± 0.20 nM) affinity profile, while its 2R-antipode (2R-OH, 6, Figure 1) provided MOR, DOR and KOR K_i values 5-, 12- and 3-times higher, respectively.

2.3. Bioluminescence resonance energy transfer assay

Based on affinity data and functional selectivity demonstrated by LP2 in GPI versus MOR and MVD versus DOR, the functional activity for MOR and DOR of LP2 (1), 2R-LP2 (4) and 2S-LP2 (5) was investigated. The compounds were evaluated for their ability to promote receptor/G-protein and receptor/β-arrestin 2 interaction in the BRET assay previously described by Molinari et al. [15]. The results are summarized in Table 2.
Table 2. Potencies and efficacies of DADLE, LP2 (1), 2R-LP2 (4) and 2S-LP2 (5) on MOR/G-protein and MOR/β-arrestin 2 interaction, and DOR/G-protein and DOR/β-arrestin 2 interaction in the BRET assay.

<table>
<thead>
<tr>
<th>Compd</th>
<th>pEC$<em>{50}$ (CL$</em>{95%}$)</th>
<th>CR$^b$</th>
<th>$\alpha$ ± SEM</th>
<th>pEC$<em>{50}$ (CL$</em>{95%}$)</th>
<th>CR$^b$</th>
<th>$\alpha$ ± SEM</th>
<th>Bias factor (CL$_{95%}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MOR/G-protein</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DADLE$^a$</td>
<td>6.89 (6.56-7.22)</td>
<td>1</td>
<td>1.00</td>
<td>5.86 (5.71-6.01)</td>
<td>1</td>
<td>1.00</td>
<td>0</td>
</tr>
<tr>
<td>LP2 (1)</td>
<td>7.90 (7.51-8.30)</td>
<td>0.10</td>
<td>0.92 ± 0.02</td>
<td>6.56 (6.22-6.90)</td>
<td>0.20</td>
<td>0.71 ± 0.09</td>
<td>0.57 (0.03-1.16)</td>
</tr>
<tr>
<td>2R-LP2 (4)</td>
<td>crc incomplete$^d$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2S-LP2 (5)</td>
<td>8.33 (7.90-8.76)</td>
<td>0.04</td>
<td>0.93 ± 0.02</td>
<td>6.82 (6.43-7.21)</td>
<td>0.11</td>
<td>0.72 ± 0.08</td>
<td>0.82 (0.22-1.41)</td>
</tr>
<tr>
<td><strong>MOR/β-arrestin 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DADLE</td>
<td>7.23 (6.88-7.57)</td>
<td>1</td>
<td>1.00</td>
<td>7.69 (7.50-7.87)</td>
<td>1</td>
<td>1.00</td>
<td>0</td>
</tr>
<tr>
<td>LP2 (1)</td>
<td>7.02 (6.83-7.21)</td>
<td>2</td>
<td>0.96 ± 0.03</td>
<td>5.65 (5.48-5.82)</td>
<td>110</td>
<td>0.90 ± 0.01</td>
<td>2.03 (1.57-2.49)</td>
</tr>
<tr>
<td>2R-LP2 (4)</td>
<td>crc incomplete$^d$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2S-LP2 (5)</td>
<td>7.49 (7.24-7.75)</td>
<td>0.55</td>
<td>1.07 ± 0.03</td>
<td>5.73 (5.40-6.07)</td>
<td>91</td>
<td>1.03 ± 0.03</td>
<td>2.31 (1.84-2.77)</td>
</tr>
</tbody>
</table>

$^a$ DADLE was used as reference agonist for calculating intrinsic activity at the MOR and DOR.

$^b$ CR is the ratio between EC$_{50}$ of tested compounds and EC$_{50}$ of standard agonist (DADLE).

$^c$ $\alpha$ is the ratio between the intrinsic activity of tested compounds and intrinsic activity of standard agonist (DADLE) as maximal-stimulated BRET ratio ($\alpha = 1$).

$^d$ Crc incomplete means that maximal effects could not be determined due to the low potency of the compound.

Data are the mean ± SEM of at least 5 separate experiments made in duplicate.
Membrane extracts taken from SH-SY5Y cells stably co-expressing the MOR/RLuc and Gβ1/RGFP fusoproteins were used in concentration-response experiments to evaluate receptor/G-protein interaction. DADLE promoted MOR/G-protein interaction in a concentration-dependent manner with potency of 6.89 and maximal effect of 0.81 ± 0.10 stimulated BRET ratio (Fig. 2, panel A).

Fig. 2. Concentration-response curve to DADLE (panel A), LP2 (1, panel B), 2R-LP2 (4, panel C) and 2S-LP2 (5, panel D) in promoting MOR/G-protein and MOR/β-arrestin 2 interaction. Data are the mean ± SEM of 5 separate experiments made in duplicate.
The intrinsic activities of tested compounds were computed as fraction of DADLE maximal-stimulated BRET ratio ($\alpha = 1$). LP2 (1) and 2S-LP2 (5) (Fig. 2, panel B and D) mimicked the maximal effect of DADLE ($\text{pEC}_{50} = 6.93$) being 10- and 30-times more potent ($\text{pEC}_{50} = 8.06$ and 8.33, respectively). Compound 2R-LP2 (4) was able to elicit a weakly stimulatory response only at the highest concentration tested (Fig. 2, panel C).

Whole SH-SY5Y cells stably expressing the MOR/RLuc and the $\beta$-arrestin 2/RGFP fusoproteins were used to evaluate MOR/$\beta$-arrestin 2 interaction. DADLE stimulated the interaction of the MOR with $\beta$-arrestin 2 in a concentration-dependent manner with $\text{pEC}_{50}$ of 5.86 and maximal effects corresponding to $0.57 \pm 0.20$ stimulated BRET ratio (Fig. 2, panel A). As for G-protein studies, the intrinsic activities of the compounds were computed as fraction of the standard agonist DADLE. Compounds LP2 (1) and 2S-LP2 (5) mimicked the stimulatory response of DADLE with slightly lower efficacy but 5- and 9-times higher potency, respectively (Fig. 2, panel B and C). 2R-LP2 (4) was inactive (Fig. 2, panel C). The results showed in Fig. 2 were used for calculating the bias factor of the ligands: LP2 (1) and 2S-LP2 (5) displayed a modest (<10 times) bias toward G-protein that reached the statistical level of significance only for the latter compound (Table 2).

In SH-SY5Y cells stably co-expressing the DOR/RLuc and the G$\beta$1/RGFP fusoproteins, DADLE promoted receptor/G-protein interaction in a concentration-dependent manner displaying a $\text{pEC}_{50}$ value of 7.23 and maximal effect of $0.42 \pm 0.04$ stimulated BRET ratio (Fig. 3, panel A). The intrinsic activities of tested compounds were computed as fraction of DADLE maximal-stimulated BRET ratio ($\alpha = 1$).
Fig. 3. Concentration response curve to DADLE (panel A), LP2 (1, panel B), 2R-LP2 (4, panel C) and 2S-LP2 (5, panel D) in promoting DOR/G-protein and DOR/β-arrestin 2 interaction. Data are the mean ± SEM of 7 separate experiments made in duplicate.

In parallel experiments, LP2 (1) and 2S-LP2 (5) (Fig. 3, panel B and D) behaved as full agonists with similar potency and similar efficacy as the standard (Table 2). Compound 2R-LP2 (4) was able to elicit a weakly stimulatory response only at the highest concentration tested (Figure 3, panel C).

Whole SH-SY5Y cells stably co-expressing the DOR/RLuc and the β-arrestin 2/RGFP fusoproteins were used to evaluate DOR/β-arrestin 2 interaction. DADLE
stimulated the interaction of the DOR with β-arrestin 2 in a concentration-dependent manner with pEC$_{50}$ of 7.69 and maximal effects corresponding to 0.47 ± 0.05 stimulated BRET ratio (Fig. 3, panel A). The intrinsic activities of the compounds under study were computed as fraction of DADLE. LP2 (1) and 2S-LP2 (5) mimicked the maximal effects of DADLE being, however, less potent (Fig. 3, panel B and D), while 2R-LP2 (4) was inactive (Fig. 3, panel C). Fig. 3 showed the comparison of the effects of each compound on the DOR/G-protein and DOR/β-arrestin 2 interaction. These results were used for calculating the bias factor of LP2 (1) and 2S-LP2 (5); both compounds showed a statistically significant and large (200-times) bias toward G-protein (Table 2).

Figure 4 shows the bias factors for LP2 (1) and 2S-LP2 (5) at MOR and DOR between G-protein and β-arrestin 2 recruitment.

**Fig. 4.** Bias factor (mean ± CL$_{95\%}$) of LP2 (1) and 2S-LP2 (5) toward G-protein and β-arrestin 2. DADLE was used as reference agonist for both receptors.
We used BRET assay to examine the capability to promote MOR and DOR/G-protein interaction of the previously synthesized 6,7-benzyomorphans with 2R-OH (6) and 2S-OH (7, Fig. S1) [7] to compare the role of the chirality. Similarly, 2S-OH (7) showed the best MOR/DOR agonist profile ($\text{pEC}_{50}^\text{MOR} = 8.18$, $\alpha = 0.87$ and $\text{pEC}_{50}^\text{DOR} = 7.84$, $\alpha = 1.13$) in comparison with the 2R-OH (6) ($\text{pEC}_{50}^\text{MOR} = 7.65$, $\alpha = 0.82$ and $\text{pEC}_{50}^\text{DOR} = 7.23$, $\alpha = 1.03$) (Table S1).

After binding at MOR and DOR, LP2 (1) and 2S-LP2 (5) are able to activate, with different efficacy, G-protein pathway over $\beta$-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. It has been demonstrated that the G-protein pathway induces analgesia, while the $\beta$-arrestin pathway is responsible for the opioid-related adverse reactions [18,19]. Recently, G-protein biased opioid agonists were identified and the relationship between in vitro bias profile and in vivo analgesia and side effects were highlighted [20-22]. Thus, the 2S-LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity.

2.4. Tail Flick Test

The antinociceptive effect of 2R-LP2 (4) and 2S-LP2 (5), i.p. administered, was examined using mouse tail-flick test [23]. Both compounds produced a dose-dependent analgesic effect compared to the group of mice treated with saline (*p<0.05 vs saline-treated mice).

In comparison to LP2 (1), featured by a maximal antinociceptive threshold reached between 45 and 60 min after injection and a prolonged analgesic effect with an $\text{ED}_{50}$ of 0.9 mg/kg [7], both isomers showed different onset and duration of the antinociceptive effect and different $\text{ED}_{50}$. In vivo evaluation of 2R-LP2 (4) established that the maximal antinociceptive activity was reached 60 min after i.p. injection and lasted over 120 min after treatment (Fig. 5, panel A). Moreover, 2R-
isomer (4) showed the antinociceptive effect at higher doses with an ED$_{50}$ of 1.8 mg/kg i.p. (1.2-2.8, CL$_{95\%}$) (Fig. 5, panel B).

Fig. 5. (A) Time-course (min) of 2R-LP2 (4) induced antinociception measured by TFL. (B) Analgesic dose-response curve ± SEM for compound 2R-LP2 (4) was plotted at 60 min post-treatment. (C) Time-course (min) of 2S-LP2 (5) induced antinociception measured by TFL. (D) Analgesic dose-response curve ± SEM for compound 2S-LP2 (5) was plotted at 30 min post-treatment. Results are expressed in seconds (s). Data are means ± SEM from 6 to 8 mice. *p<0.05 vs saline-treated mice.

A robust antinociceptive effect was achieved at very low doses of 2S-LP2 (5), with an ED$_{50}$ of 0.6 mg/kg i.p. (0.4-0.8, CL$_{95\%}$) (Fig. 5, panel D), that revealed its highest effect already at 30 min post-administration (Fig. 5, panel C). At the tested doses, 2R-LP2 (4) and 2S-LP2 (5) didn’t affect significantly behavior responses (i.e. locomotor activity and sedation; unpublished data).
Therefore, 2R-LP2 (4) and 2S-LP2 (5) exhibited a different profile in modulating acute thermal nociception. The more potent activity of 2S-LP2 (5) translated the MOR/DOR affinity (binding assay) and the full MOR/DOR agonist activity (BRET assay) into the behavioral antinociceptive assay. Therefore, in vivo results confirmed that S-configuration of N-substituent improved the pharmacological profile in comparison with 2R-isomer (4). We demonstrated the same trend for 6,7-benzomorphan 2S-OH (7) that showed an ED50 of 1.0 mg/kg i.p. (0.7-1.5, CL95%) better than the 2R-isomer (2R-OH, 6) with an ED50 of 1.3 mg/kg i.p. (0.9-2.1, CL95%) [7].

2R-LP2 (4) in vivo profile does not reflect in vitro data. Indeed, 2R-LP2 (4) exhibited only 3-times difference in antinociceptive efficacy than 2S-LP2 (5) but about 25-times less affinity for MOR, and about 58-times less affinity for DOR, resulting a very weak agonist at MOR and inactive at DOR. This behavior could be due to 2R-LP2 (4) pharmacokinetic properties or stability [1,2,24].

3. Conclusion

The pivotal role of the stereocenter at the N-substituent of the 6,7-benzomorphan scaffold was pointed out combining synthetic and pharmacological approaches. It is well known that the stereochemistry could affect pharmacological parameters such as potency, intrinsic efficacy and binding affinity in ligand-opioid receptor interaction. The development of a single isomer in place of a previous racemic mixture, a process known as “chiral switching”, could provide potential advantages such as an improved therapeutic index, decreased side-effects, a faster onset of action and a reduced liability for drug-drug interactions [25].

2R-(4) and 2S-LP2 (5) were featured by a qualitatively similar but quantitatively different pharmacological fingerprint in agreement with the importance of
stereoselective drug-opioid receptor interaction. Specifically, 2S-LP2 (5) showed an antinociceptive effect at a very low dose with potency 1.5- and 3-times increased in comparison to LP2 (1) and R-antipode (4), respectively. The in vivo effect of 2S-LP2 (5) was consistent with its MOR and DOR affinity profile combined to the improved multitarget MOR/DOR full agonist profile. Moreover, 2S-LP2 (5) resulted a biased MOR/DOR agonist. It has been demonstrated that biased opioid ligands selectively activate G-protein signalling leading to more effective antinociceptive drugs with fewer side effects. Such biased ligands could have a major impact on modern drug discovery and represent a new strategy for the development of more tolerated drug candidates [26,27]. Indeed, their functional selectivity for G-protein signalling and reduced β-arrestin 2 recruitment could be consistent with their effectiveness in chronic pain conditions management [28,29]. Thus, the advantageous pharmacological profile of 2S-LP2 (5) could be the result of its capability to simultaneously target MOR and DOR, that it has been widely demonstrated to be a valid strategy to obtain an improved antinociceptive effect coupled with an improved tolerability, combined with its capability to selectively promote the G-protein signalling.

4. Experimental section

4.1. Chemistry

4.1.1. General methods

General methods are reported in Supporting Information. All reported compounds had a purity of at least 95%.

4.1.2. General procedure for the synthesis of tosylate intermediates (2-3)
The synthesis of tosylate intermediates 2-3 was performed as previously reported [7] using (R)-(−)-2-methoxy-2-phenylethanol or (S)-(−)-2-methoxy-2-phenylethanol (see Supporting Information).

4.1.2.1. (R)-2-methoxy-2-phenylethyl 4-methylbenzenesulfonate (2). Waxy solid (94%). Mp: 52-55 °C. $[\alpha]_{D}^{25} = -42.9^\circ$ (c 1.05, CHCl$_3$). IR (CHCl$_3$) 3019, 2943, 1598, 1456, 1362, 1215, 1176 cm$^{-1}$. $^1$H NMR (200 MHz, CDCl$_3$): $\delta$ 7.76-7.72 (m, 2H, CH Ts), 7.32-7.26 (m, 7H, CH Ts and aryl), 4.42-4.39 (m, 1H, CH-O), 4.09-4.03 (m, 2H, CH$_2$), 3.23-3.20 (t, 3H, -OCH$_3$), 2.44 (s, 3H, CH$_3$). $^{13}$C NMR (50 MHz, CDCl$_3$) $\delta$ 144.79, 136.63, 132.91, 129.69, 128.62, 128.55, 127.83, 126.85, 81.15, 72.79, 56.98, 21.46 (see Supporting Information Figure S2-S4).

4.1.2.2. (S)-2-methoxy-2-phenylethyl 4-methylbenzenesulfonate (3). Waxy solid (74%). Mp 54-55 °C. $[\alpha]_{D}^{25} = +42.2^\circ$ (c 1.02, CHCl$_3$). IR (CHCl$_3$) 3019, 2934, 1598, 1455, 1361, 1215, 1176 cm$^{-1}$. $^1$H NMR (200 MHz, CHCl$_3$) $\delta$ 7.76-7.72 (m, 2H, CH Ts), 7.43-7.22 (m, 7H, CH Ts and aryl), 4.44-4.39 (m, 1H, CH-O) 4.09-4.03 (m, 2H, CH$_2$), 3.23-3.21 (t, 3H, -OCH$_3$), 2.44 (s, 3H, CH$_3$). $^{13}$C NMR (50 MHz, CHDCl$_3$) $\delta$ 144.67, 136.73, 132.92, 129.72, 128.65, 128.57, 127.86, 126.88, 81.12, 72.85, 57.01, 21.59. (see Supporting Information Figure S5-S7).

4.1.3. General procedure for the synthesis of N-Substituted (−)-cis-N-normetazocine diastereomers (4-5)

Compounds 4-5 were obtained as previously reported [7] (see Supporting Information).
4.1.3.1. (2R,6R,11R)-3-((R)-2-methoxy-2-phenylethyl)-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methanobenzod[azocin-8-ol (4). White solid (62%). Mp 176-180 °C; [α]$_D^{25}$ = − 53.7° (c 1.05, EtOH). $^1$H NMR (200 MHz, CDCl$_3$, free base) δ 7.32-7.19 (m, 5H, CH aryl), 6.83 (d, 1H, $J = 8.2$ Hz, CH benzomorphan), 6.65 (d, 1H, $J = 2.2$ Hz, CH benzomorphan), 6.55 (dd, 1H, $J = 8.2, 2.2$ Hz, CH benzomorphan), 4.35 (d, 1H, CH-O), 3.13 (s, 3H, -OCH$_3$), 2.89-2.55 (m, 6H, CH, CH$_2$ benzomorphan and CH$_2$), 2.23-2.11 (m, 1H, CH benzomorphan), 1.90-1.82 (m, 2H, CH$_2$ benzomorphan), 1.24 (s, 3H, CH$_3$ benzomorphan), 1.18-1.10 (m, 1H, CH benzomorphan), 0.73 (d, 3H, CH$_3$ benzomorphan). $^{13}$C NMR (50 MHz, CDCl$_3$, free base) δ 154.29, 143.05, 141.07, 128.33, 128.11, 127.66, 127.50, 126.66, 113.06, 112.32, 81.68, 62.12, 58.7, 56.60, 46.74, 41.12, 40.33, 36.06, 25.29, 23.89, 14.11(see Supporting Information Figure S8-S9). MS m/z [M]$^+$ 351.4. Anal (C$_{23}$H$_{29}$NO$_2$·HCl) C, H, N (see Supporting Information Table S2).

4.1.3.2. (2R,6R,11R)-3-((S)-2-methoxy-2-phenylethyl)-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methanobenzod[azocin-8-ol (5). White solid (60%). Mp 177-180 °C; [α]$_D^{25}$ = + 68.3° (c 1.05, EtOH). $^1$H NMR (200 MHz, CDCl$_3$, free base) δ 7.25-7.19 (m, 5H, CH aryl), 6.83 (d, 2H, $J = 8.2$ Hz, CH benzomorphan), 6.65 (d, 1H, $J = 2.0$ Hz, CH benzomorphan), 6.55 (dd, 1H, $J = 8.2, 2.2$ Hz, CH benzomorphan), 4.42 (d, 1H, CH-O), 3.15 (s, 3H, -OCH$_3$), 2.97-2.55 (m, 6H, CH, CH$_2$ benzomorphan and CH$_2$), 2.01-1.85 (m, 3H, CH and CH$_2$ benzomorphan), 1.25 (s, 3H, CH$_3$ benzomorphan), 1.18-1.15 (m, 1H, CH benzomorphan), 0.76 (m, 3H, CH$_3$ benzomorphan). $^{13}$C NMR (50 MHz, CDCl$_3$, free base) δ 154.51, 142.79, 140.55, 128.43, 128.15, 127.86, 127.76, 126.57, 113.16, 112.25, 81.61, 61.88, 58.79, 56.71, 46.02, 41.05, 40.91, 35.71, 25.18, 24.05, 14.01(see Supporting Information Figure
S10-S11). MS m/z [M]+ 351.4. Anal (C_{23}H_{29}NO_{2}·HCl) C, H, N (see Supporting Information Table S2).

4.2. Receptor binding assays

4.2.1. Drugs and reagents

4.2.2. Competitive Radioligand Binding Assay
MOR, DOR and KOR binding experiments were performed on rat or guinea pig brain membranes according to the experimental protocol described by Spetea et al. [30] without modifications, as reported elsewhere [31]. Protein concentration was determined by Lowry’s method using bovine serum albumin as standard [32]. Binding experiments at MOR and DOR were carried out by incubating 0.4 mg/mL and 0.5 mg/mL of rat brain membrane proteins, respectively for 45 min at 35 °C either with 1 nM [^3]H-DAMGO (48.4 Ci/mM) or 2 nM [^3]H-DPDPE (52.7 Ci/mM) in 50 mM Tris-HCl (pH 7.4). Regarding KOR binding assays, guinea pig brain membranes (0.5 mg/mL) were incubated for 30 min at 30 °C with 1 nM [^3]H-(+)-U69,593 (42.69 Ci/mM). Test compounds were added in concentration ranging from 10^{-5} to 10^{-11} M. Nonspecific binding was assessed in the presence of 10 µM of unlabeled naloxone. The reaction was terminated by filtering the solution through Whatman GF/B glass fiber filters, which were presoaked for 1h in a 0.5% polyethylenimine solution. Filters were washed with ice cold buffer (2×4 mL), dried, soaked in 4 mL of "Ultima Gold MV" scintillation cocktail and counted on a Beckman LS 6500 liquid scintillation counter.
4.2.3. Data analysis

$K_i$ values were calculated using nonlinear regression analysis to fit a logistic equation to the competition data using GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, USA).

4.3. Functional assay

4.3.1. Drugs and reagents

All cell culture media and supplements were from Invitrogen (Thermo Fisher Scientific Inc. MA, USA). All other reagents were from Sigma Chemical Co. (Poole, U.K.) and were of the highest purity available. DADLE was from Sigma Chemical Co. (Poole, U.K.), DADLE was solubilized in bidistilled water, while compounds 1, 4 and 5 were solubilized in DMSO (5% v/v) at a final concentration of 10 mM. Stock solutions of ligands were stored at -20 °C.

4.3.2. BRET assay

SH-SY5Y cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)/HAMS F12 (1:1) supplemented with 10% fetal bovine serum, penicillin G (100 units/mL), streptomycin (100 µg/mL), L-glutamine (2 mM), fungizone (1 µg/mL), geneticin (G418; 400 µg/mL) and hygromycin B (100 µg/mL) in a humidified atmosphere of 5% CO$_2$ at 37 °C. Cell lines permanently co-expressing the different pairs of fusion proteins (MOR-RLuc/G$\beta$1-RGFP, MOR-RLuc/$\beta$-arrestin 2-RGFP, DOR-RLuc/G$\beta$1-RGFP, and DOR-RLuc/$\beta$-arrestin 2-RGFP) were prepared using the pantropic retroviral expression system by Clontech as described previously [33]. For G-protein experiments enriched plasma membrane aliquots from transfected cells were prepared by differential centrifugation; cells were detached with PBS/EDTA solution (1 mM, pH 7.4 NaOH) then, after 5 min 500 g centrifugation,
Dounce-homogenized (30 strokes) in cold homogenization buffer (Tris 5 mM, EGTA 1 mM, DTT 1 mM, pH 7.4 HCl) in the presence of sucrose (0.32 M). Three following centrifugations were performed at 10 min 1000 g (4 °C) and the supernatants kept. Two 20 min 24,000 g (4 °C) subsequent centrifugations (the second in the absence of sucrose) were performed for separating enriched membranes that after discarding the supernatant were kept in ultrapure water at -80 °C [34]. The protein concentration in membrane preparations was determined using the QPRO-BCA kit (Cyanagen Srl, Bologna, IT) and the spectrophotometer Ensight (Perkin Elmer, Waltham, US).

Luminescence in membranes and cells was recorded in 96-well white opaque microplates (PerkinElmer, Waltham, MA, USA) using the luminometer Victor 2030 (PerkinElmer, Waltham, MA, USA). For the determination of receptor/G-protein interaction, membranes (3 µg of protein) prepared from cells co-expressing MOR-RLuc/Gβ1-RGFP or DOR-RLuc/Gβ1-RGFP were added to wells in DPBS. For the determination of receptor/β-arrestin 2 interaction, cells co-expressing MOR-RLuc/β-arrestin 2-RGFP or DOR-RLuc/β-arrestin 2-RGFP were plated 24h before the experiment (100,000 cells/well). The cells were prepared for the experiment substituting the medium with PBS with MgCl₂ (0.5 mM) and CaCl₂ (0.9 mM). Coelenterazine at a final concentration of 5 µM was injected 15 minutes prior reading the cell plate. Different concentrations of ligands in 20 µL of PBS - BSA 0.01 % were added and incubated 5 min before reading luminescence. All the experiments were performed at room temperature.

4.3.3. Data analysis and terminology

The pharmacological terminology adopted in this paper were consistent with IUPHAR recommendations [35]. All data were expressed as the mean ± standard error of the mean (SEM of n experiments). For potency values 95% confidence limits
(CL$_{95\%}$) were indicated. BRET data were calculated as BRET ratio between CPS measured for the RGFP and RLuc light emitted using 510(10) and 460(25) filters (PerkinElmer, Waltham, MA, USA), respectively. Maximal agonist effects were expressed as fraction of the DADLE maximal effects that was determined in every assay plate. Agonist potencies were given as pEC$_{50}$ i.e. the negative logarithm to base 10 of the molar concentration of an agonist that produces 50% of the maximal effect of that agonist. Concentration-response curves to agonists were fitted to the classical four-parameter logistic nonlinear regression model:

$$\text{Effect} = \text{baseline} + \frac{E_{\text{max}} - \text{baseline}}{1 + 10^{\log_{10} \text{EC}_{50} - \log_{10} \text{response} \cdot \text{Hill slope}}}$$

Curve fitting was performed using PRISM 6.0 (GraphPad Software In., San Diego, USA). pEC$_{50}$ was the concentration of agonist producing a 50% maximal response and n was the Hill coefficient of the concentration-response curve to the agonist. CR was the ratio between EC$_{50}$ of ligand and EC$_{50}$ of standard agonist (DADLE). Maximal effects have been statistically analyzed with one-way ANOVA followed by the Dunnett’s post hoc test for multiple comparisons; P values less than 0.05 were considered statistically significant.

Bias factors were calculated by choosing DADLE as standard unbiased ligand. The concentration response curves of each compound were fitted to the Black-Leff operational model described by Nagi & Pineyro [36]:

$$\text{response} = \frac{[A^n] \tau^n E_m}{[A]^n \tau^n + ([A] + K_A)^n}$$

where [A] is the agonist concentration, the maximal response of the system is given by $E_m$, $n$ is a fitting parameter for the slope, the affinity of the agonist is represented by the equilibrium dissociation constant of the agonist-receptor complex ($K_A$), and the efficacy of the agonist is defined by $\tau$. $\tau$ and $K_A$ are descriptive parameters of intrinsic
efficacy and binding affinity and may be directly obtained by fitting experimental
data to the operational equation and can be expressed as “transduction coefficients”
$\log(\tau/K_A)$. The relative efficiency of agonists producing activation of any pathways
can thus be quantified with a “normalized” transduction coefficient, namely
$\Delta \log(\tau/K_A)$. Finally, the bias factors were calculated as difference between $\Delta \log(\tau/K_A)$
values for a given agonist between the pathways (G protein and β-arrestin 2):

$$\Delta \Delta \log(\tau/K_A) \text{ (bias factor)} = \Delta \log(\tau/K_A)_{G \text{ protein}} - \Delta \log(\tau/K_A)_{\beta\text{-arrestin 2}}$$

Bias factors are expressed as the mean ± SEM of at least 5 independent experiments.

4.4. In vivo pharmacology

4.4.1. Animals

Male Swiss CB1 mice (Envigo Laboratories, S.Pietro al Natisone (UD)) weighing 25-
30 g were housed six to a cage. Animals were kept at a constant room temperature (25 ± 1 °C) under a 12:12h light and dark cycle with free access to food and water. Each
mouse was used for only one experiment. Experimental procedures were approved by
the Local Ethical Committee (IACUC) and conducted in accordance with
international guidelines as well as European Communities Council Directive and
National Regulations (CEE Council 86/609 and DL 116/92).

4.4.2. Nociceptive Test

Nociception was evaluated by the radiant heat tail-flick test [37,38]. Briefly, it
consisted of irradiation of the lower third of the tail with an infrared source (Ugo
Basile, Comerio, Italy). The day before the experiment, mice were habituated to the
procedure for measuring nociception threshold. Experiments were performed at room
temperature (25 ± 1 °C). The basal pre-drug latency was established between 3 and 5
s and was calculated as the average of the first three measurements, which were
performed at 5 min intervals. A cutoff latency of 20 s was established to minimize damage to the tail. All tested compounds were dissolved in pyrogen-free isotonic saline (Baxter Healthcare, Deerfield, IL) and DMSO (5%) and were administered to mice i.p. Post-treatment tail flick latencies (TFLs) were determined at 30, 60, 90, 120, 150 and 180 min after i.p. injection.

4.4.2. Statistical Analysis

All values were presented as means ± SD. Intergroup comparisons were assessed using an initial two-way analysis of variance (ANOVA) followed by Duncan’s multiple range post-hoc test. Differences were considered significant when *p < 0.05. Effective dose-50 (ED<sub>50</sub>) values were calculated using least-squares linear regression analysis followed by calculation of 95% confidence limits (CL<sub>95%</sub>) by the method of Bliss [39,40].

Conflicts of interest

The authors declare no other conflicts of interest.

Acknowledgements

This work was supported by University of Catania (PdR 2016-2018 - UPB 57722172104) to Lorella Pasquinucci. The authors gratefully acknowledge Fabbrica Italiana Sintetici (Italy) for providing (±)-cis-N-normetazocine.

Appendix A. Supplementary data

Supplementary data related to this article can be found at

References


[27] Kennedy, NM; Schmid, CL; Ross, NC; Lovell, KM; Yue, Z; Chen, YT; Cameron, MD; Bohn, LM; Bannister, TD. Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias. J. Med. Chem. 61 (2018) 8895–8907, DOI: 10.1021/acs.jmedchem.8b01136.


Highlights

1. The stereocenter role at the N-substituent of the 6,7-benzomorphan scaffold was investigated.
2. 2R- and 2S-diastereoisomers of the multitarget opioid ligand LP2 were synthesized.
3. 2S-LP2 showed a better pharmacological profile than 2R-LP2 in in vitro and in vivo assays.
4. 2S-LP2 resulted a biased multitarget MOR/DOR agonist.
5. 2S-LP2 elicited an antinociceptive potency 1.5- and 3-times higher than LP2 and R-antipode.